Cherubini, Alessandro http://orcid.org/0000-0003-4756-2046
Ostadreza, Mahnoosh
Jamialahmadi, Oveis
Pelusi, Serena
Rrapaj, Eniada
Casirati, Elia http://orcid.org/0000-0001-5938-0149
Passignani, Giulia
Norouziesfahani, Marjan
Sinopoli, Elena
Baselli, Guido http://orcid.org/0000-0002-0234-6828
Meda, Clara
Dongiovanni, Paola
Dondossola, Daniele
Youngson, Neil
Tourna, Aikaterini
Chokshi, Shilpa http://orcid.org/0000-0003-1735-8538
Bugianesi, Elisabetta
Ronzoni, Luisa
Bianco, Cristiana
Cerami, Laura
Torcianti, Veronica
Periti, Giulia
Margarita, Sara
Carpani, Rossana
Malvestiti, Francesco
Marini, Ilaria
Tomasi, Melissa
Lombardi, Angela
Rondena, Jessica
Maggioni, Marco
D’Ambrosio, Roberta
Vaira, Valentina
Fracanzani, Anna Ludovica
Rosso, Chiara
Pennisi, Grazia
Petta, Salvatore
Liguori, Antonio
Miele, Luca
Tavaglione, Federica
Vespasiani-Gentilucci, Umberto
Dallio, Marcello
Federico, Alessandro
Soardo, Giorgio
Pihlajamäki, Jussi
Männistö, Ville
Della Torre, Sara http://orcid.org/0000-0001-9498-5266
Prati, Daniele
Romeo, Stefano http://orcid.org/0000-0001-9168-4898
Valenti, Luca http://orcid.org/0000-0001-8909-0345
,
Funding for this research was provided by:
Ministero della Salute (RF-2016-02364358, RF-2021-12373889, PNRR-MAD-2022-12375656, Rete Cardiologica “CV-PREVITAL”, Ricerca Corrente, Rete Cardiologica “CV-PREVITAL”, Ricerca Corrente)
EC | Horizon 2020 Framework Programme (777377, 101016726, 101096312)
Gilead Sciences (Gilead_IN-IT-989-5790)
Diabetesliitto (EVO/VTR grants 2005–2021)
Article History
Received: 31 March 2023
Accepted: 21 August 2023
First Online: 25 September 2023
Change Date: 24 January 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-02817-x
Competing interests
: The authors declare that they have no conflicts of interest relevant to the present study. L.V. has received speaking fees from MSD, Gilead, AlfaSigma and AbbVie, served as a consultant for Gilead, Pfizer, AstraZeneca, Novo Nordisk, Intercept, Diatech Pharmacogenetics, Ionis Pharmaceuticals, Boeringher Ingelheim and Resalis, and received research grants from Gilead. D.P. served as a consultant for, and has received speaking fees, travel grants and research grants from, Macopharma, Ortho Clinical Diagnostics, Grifols, Terumo, Immucor, Diamed and Diatech Pharmacogenetics.